Filing Flows › Hinge Health (HNGE) › Q3 2026 › vs Q3 2025
Hinge Health (HNGE) Q3 2026 vs Q3 2025 (year over year)
Hinge Health's revenue rose $80.8M (+52%) from $154M in Q3 2025 to $235M in Q3 2026. Gross margin 87.0% against 81.8% (+5.1 pts).
Hinge Health, Q3 2026: revenue $235M (+52% year over year), operating margin 21.4%, net earnings $57.4M, operating cash flow $115M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 87.0% | 81.8% | +5.1 pts |
| Operating margin | 21.4% | -4.0% | +25.4 pts |
| Net margin | 24.4% | -1.2% | +25.6 pts |
| Free cash flow margin | 47.9% | 52.7% | -4.8 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $235M | $154M | $80.8M | +52% |
| Gross profit | $204M | $126M | $78.1M | +62% |
| Cost of revenue | $30.6M | $28.0M | $2.6M | +9% |
| Other income, net | $3.4M | $4.5M | −$1.1M | -24% |
| Operating profit | $50.3M | −$6.1M | $56.4M | — |
| Operating expenses | $154M | $132M | $21.7M | +16% |
| Pre-tax earnings | $53.7M | −$1.6M | $55.4M | — |
| Research & development | $37.5M | $31.9M | $5.6M | +17% |
| Sales & marketing | $85.2M | $63.5M | $21.7M | +34% |
| General & admin | $31.3M | $36.9M | −$5.6M | -15% |
| Income tax benefit | $3.7M | −$206K | $3.9M | — |
| Net earnings | $57.4M | −$1.8M | $59.2M | — |
| Depreciation & amortization | $2.2M | $1.3M | $957K | +76% |
| Share-based compensation | $19.5M | $34.8M | −$15.3M | -44% |
| Working capital & other | $35.4M | $48.1M | −$12.7M | -26% |
| Operating cash flow | $115M | $82.4M | $32.2M | +39% |
| Free cash flow (company-reported) | $113M | $81.3M | $31.4M | +39% |
| Purchases of property, equipment and software (including capitalized internal use software) | $1.9M | $1.1M | $827K | +74% |
Questions
How much did Hinge Health's revenue grow year over year in Q3 2026?
Hinge Health's revenue rose $80.8M (+52%) from $154M in Q3 2025 to $235M in Q3 2026. Gross margin 87.0% against 81.8% (+5.1 pts).